Literature DB >> 19876861

Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.

Chip Gresham1, Michael Levine, Anne-Michelle Ruha.   

Abstract

A 50-year-old man presented to the emergency department (ED) following an overdose of his "blood thinners." The patient had become increasingly depressed over financial concerns, prompting a suicide attempt. He declined to provide any details regarding his current medications or his past medical history. A review of the computerized medical record, however, revealed he had a Factor V Leiden mutation with multiple venothromboembolic events. He previously had an inferior vena cava filter placed, and had received tissue plasminogen activator (tPA) for a cerebrovascular accident. A toxicology consult was obtained in the ED.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19876861      PMCID: PMC3550411          DOI: 10.1007/bf03178275

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  52 in total

1.  Editorial comment--an approach to the estimation of the risk of TTP during clopidogrel therapy.

Authors:  Saran Jonas; Giacinto Grieco
Journal:  Stroke       Date:  2004-02       Impact factor: 7.914

2.  Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children.

Authors:  Jeremy D Robertson; Leonardo Brandao; Suzan Williams; Cindy Ing; Anthony K C Chan
Journal:  Thromb Res       Date:  2008-07-07       Impact factor: 3.944

3.  Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.

Authors:  Mohammed Abuzahra; Manu Pillai; Angel Caldera; W Bryan Hartley; Rafael Gonzalez; Jaromir Bobek; Hisham Dokainish; Nasser Lakkis
Journal:  Am J Cardiol       Date:  2008-05-28       Impact factor: 2.778

Review 4.  Comparative pharmacokinetics of LMWHs.

Authors:  M M Samama; G T Gerotziafas
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

Review 5.  Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Authors:  Paris J Abrams; Christopher R Emerson
Journal:  Pharmacotherapy       Date:  2009-02       Impact factor: 4.705

6.  The direct factor Xa inhibitor rivaroxaban.

Authors:  Abhishek K Verma; Timothy A Brighton
Journal:  Med J Aust       Date:  2009-04-06       Impact factor: 7.738

Review 7.  New anticoagulants.

Authors:  Kenneth A Bauer
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

Review 8.  Rivaroxaban: an oral direct inhibitor of factor Xa.

Authors:  Michael P Gulseth; Jessica Michaud; Edith A Nutescu
Journal:  Am J Health Syst Pharm       Date:  2008-08-15       Impact factor: 2.637

Review 9.  ADP receptor antagonism: what's in the pipeline?

Authors:  Dominick J Angiolillo
Journal:  Am J Cardiovasc Drugs       Date:  2007       Impact factor: 3.571

Review 10.  Fondaparinux: a new antithrombotic agent.

Authors:  Judy W M Cheng
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

View more
  3 in total

Review 1.  Emergency reversal of anticoagulation: novel agents.

Authors:  Michael Levine; Joshua N Goldstein
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 2.  Anticoagulation drug therapy: a review.

Authors:  Katherine Harter; Michael Levine; Sean O Henderson
Journal:  West J Emerg Med       Date:  2015-01-12

Review 3.  A meta-analysis on anticoagulation after vascular trauma.

Authors:  Shujhat Khan; Hussein Elghazaly; Areeb Mian; Mansoor Khan
Journal:  Eur J Trauma Emerg Surg       Date:  2020-02-17       Impact factor: 3.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.